INTRODUCTION {#S1}
============

Cell cycle speed varies widely and undergoes dynamic changes during development and tissue homeostasis, linking characteristic cycling behavior with fate-specifying events ([@R9]; [@R65]). The cleavage divisions initiating embryogenesis follow well-defined rapid and synchronous mitotic cycles ([@R52]), with the onset of gastrulation coinciding with cell cycle lengthening and diversification ([@R15]; [@R51]). In mammals, a characteristically fast cell cycle is seen in embryonic stem cells (ESCs), and pluripotency exit is coupled with dramatic restructuring and lengthening of the cell cycle ([@R6]; [@R78]). Post-development, highly regulated cell cycles are seen across many tissues, including blood ([@R54]; [@R56]), brain ([@R82]), intestine ([@R77]), and others ([@R44]; [@R73]). In tissues with low cellular turnover such as the heart, cells' inability to re-enter the cell cycle appears to underlie poor regenerative capacity ([@R74]). In high-turnover tissues such as blood, lifelong hematopoiesis is sustained by hematopoietic stem cells (HSCs), which divide rarely ([@R80]), and their ability to maintain quiescence is essential for function ([@R56]). Contrastingly, committed myeloid progenitors proliferate rapidly under homeostasis ([@R55]). Granulocyte-macrophage progenitors (GMPs) in particular appear to be one of the most proliferative cell types ([@R55]) and are known to possess unique cell fate plasticity beyond the hematopoietic fate ([@R25]; [@R81]).

Cell cycle abnormalities characterize certain disease states, such as cancer. Many oncogenes and tumor suppressor genes, such as Rb, p53, and c-Myc ([@R8]; [@R22]; [@R38]), converge on the (dys)regulation of the cell cycle. Conventional chemotherapies often attempt to blunt cancer growth by targeting the cell cycle ([@R29]; [@R60]), but the efficacy can be compromised by proliferative heterogeneity among cancer cells ([@R20]). Relapse due to development of chemo-resistance is thought to be related to the presence of quiescent cancer cells at the time of treatment ([@R10]). Recently, cyclin D-CDK4 has been shown to destabilize PD-L1 to induce tumor immune surveillance escape ([@R83]).

Overall, understanding the consequences of diverse cycling behaviors in development, regeneration, and disease is fundamentally important. However, convenient assessment of cell cycle speed, especially in live cells of complex tissues, remains technically challenging.

Existing strategies for cell cycle analysis have several limitations. First, they mostly convey cell cycle phase ([@R58]), not duration. Although fast dividing populations tend to contain more S/G2/M cells at any given time, high S/G2/M frequency could also indicate cell-cycle arrest at these phases. Second, although image tracking is direct and accurate for determining cell cycle length, many cells *in vivo* are not amenable to microscopy, because of their deep location, their migratory behavior, and the prohibitively long duration to observe at least two consecutive mitoses. Microscopy-based analysis does not enable physical separation of fast versus slow cycling cells for downstream assays. Third, label retention assays ([@R46]) reflect divisional history but give little information about the current cycling state. Although such techniques have yielded tremendous knowledge on stem cell quiescence *in vivo* ([@R19]; [@R73]; [@R80]), cycling kinetics become difficult to resolve after the label is chased beyond the detection limit. The resolution of such methods is also constrained by how similar the cells are to each other ([@R25]). Some of the labels are cytotoxic or require fixation to visualize ([@R80]). To overcome these limitations, we developed a genetically encoded color-changing fluorescent protein that reports the cell cycle speed of live cells *in vitro* and *in vivo* in a ratiometric manner.

RESULTS {#S2}
=======

Mathematical Modeling Predicts Long- and Short-Lived Molecules to Be Differentially Susceptible to Reduction by Cell Division {#S3}
-----------------------------------------------------------------------------------------------------------------------------

The steady-state level of a given molecule is determined by the sum of its biogenesis and turnover. Turnover occurs by active catalysis and by passive dilution when cells divide ([@R17]). The extent to which cell division influences a molecule's levels depends on its half-life ([Data S1](#SD1){ref-type="supplementary-material"}). When the timescale of degradation is significantly shorter than the length of the cell cycle, the contribution from active turnover dominates. An example of this is the inhibitor of NF-κB, or IκBa, which undergoes enhanced degradation upon phosphorylation within minutes of signaling, leading to NF-κB activation ([@R27]). However, when molecular lifespan approaches the length of the cell cycle, dilution by cell division becomes the main mode of removal. This phenomenon is seen during myeloid fate commitment from multipotent hematopoietic progenitors, where the stable PU.1 protein accumulates as the cell cycle lengthens ([@R41]). Therefore, the intracellular concentration of a stable species varies more than that of an unstable species in response to cell division rate. The different behaviors of short- versus long-lived molecules in relation to cell cycle length are illustrated in [Figure 1A](#F1){ref-type="fig"}, suggesting a potential strategy for ranking cell cycle length by measuring two molecules (e.g., fluorescent proteins) that are distinct in their half-lives.

To exploit the differential susceptibility of labile and stable molecular species to cell division-mediated halving, we turned to the fluorescent timer (FT): a color-changing protein that emits blue fluorescence when newly synthesized, irreversibly turning red after a characteristic time delay ([@R68]) ([Figure 1B](#F1){ref-type="fig"}; [Figure S1A](#SD1){ref-type="supplementary-material"}). The blue and red proteins are synthesized orthogonally in a stoichiometric 1:1 manner, because the blue species is a folding intermediate of the red, whose abundance can be measured separately by fluorescence microscopy or flow cytometry. Importantly, the blue form of the FT is lost soon after synthesis, when it converts to the red form, which has a much longer half-life ([Figure 1B](#F1){ref-type="fig"}; [Figure S1A](#SD1){ref-type="supplementary-material"}). Thus, the blue form models the short-lived molecule, whose concentration is less variable across different cell cycle rates compared with the stable red form ([Figures S1B](#SD1){ref-type="supplementary-material"}--[S1D](#SD1){ref-type="supplementary-material"}). From a mathematical model describing the kinetics of this fluorescence conversion and degradation, we find that the steady-state blue/red fluorescence ratio (BR) scales inversely with cell cycle length ([Data S2](#SD1){ref-type="supplementary-material"}), with a shorter (longer) cell cycle length producing a higher (lower) BR. Thus, BR decreases as cell cycle lengthens or slows ([Figure 1C](#F1){ref-type="fig"}; [Figures S1B](#SD1){ref-type="supplementary-material"}--[S1D](#SD1){ref-type="supplementary-material"}), providing a strategy to distinguish cycling rates ([Figure 1D](#F1){ref-type="fig"}).

H2B-FT Fusion Proteins Undergo Blue-to-Red Conversion and Are Suitable for Proliferative Cells {#S4}
----------------------------------------------------------------------------------------------

The FT was fused to the C terminus of histone H2B ([Figure 2A](#F2){ref-type="fig"}), a widely used strategy with minimal adverse consequences ([@R28]). This localized FT signal to the chromatin ([Figure 2B](#F2){ref-type="fig"}), facilitating nuclear segmentation and image processing. To assess whether tagging the FT onto a histone interferes with its color-changing properties, we imaged HeLa cells expressing H2B-FT under the control of a tetracycline-inducible (TetO) promoter ([Figure 2A](#F2){ref-type="fig"}). HeLa cells transduced with the "medium" FT variant ([@R68]) ([Figure S1A](#SD1){ref-type="supplementary-material"}) produced detectible blue signal \~2 h after adding doxycycline (Dox) ([Figures 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}; [Video S1](#SD3){ref-type="supplementary-material"}), a time delay presumably required for Dox-induced transcription and translation. Approximately 1.5 h after the appearance of blue fluorescence, red signal emerged as the first wave of FT molecules underwent maturation ([Figure 2C](#F2){ref-type="fig"}; [Video S1](#SD3){ref-type="supplementary-material"}). The average cellular level of red fluorescence rose for at least the next 26 h ([Figure 2E](#F2){ref-type="fig"}). In contrast, the average blue level plateaued much sooner (after \~7 h) ([Figure 2D](#F2){ref-type="fig"}), as expected for a molecule that is lost (in this case converted to red) shortly after synthesis. To confirm the divergent turnover times for the blue and red FT, we treated cells with Dox briefly ("Dox pulse"; [Figure 2F](#F2){ref-type="fig"}). Upon Dox washout, blue signal dropped below detection within 7 h ([Figures 2D](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}), while red signal persisted for at least 24 h ([Figures 2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}), confirming that the red H2B-FT is more stable than the blue form. Mathematical simulation predicts that the FT reports cell cycle speed only after its expression reaches steady-state ([Figures S1B](#SD1){ref-type="supplementary-material"}--[S1D](#SD1){ref-type="supplementary-material"}). When newly expressed, the blue form should be over-represented independent of cell cycle effects because insufficient time has elapsed for red molecules to accumulate. In agreement with the model, cells had a higher BR within the first 24 h of Dox induction compared with cells maintained continuously in Dox ([Figure 2G](#F2){ref-type="fig"}; [Videos S1](#SD3){ref-type="supplementary-material"} and [S2](#SD4){ref-type="supplementary-material"}). As such, all subsequent *in vitro* experiments were conducted after at least 48 h on Dox.

We next assessed the reduction in H2B-FT-red signal contributed by mitosis-dependent and mitosis-independent processes. Single cells (primary mouse embryonic fibroblasts \[MEFs\] or HeLa cells) were tracked over 20 h after Dox washout ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2B](#SD1){ref-type="supplementary-material"}). Red fluorescence decreased by 15% in non-dividing MEFs (irradiated or naturally non-dividing by chance) ([Figure S2C](#SD1){ref-type="supplementary-material"}), while mitosis led to a drop of \~50% ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2C](#SD1){ref-type="supplementary-material"}). Similar to MEFs, mitosis caused a drop of \~50% in red fluorescence of dividing HeLa cells, as long as all progeny were accounted for ([Figures S2B](#SD1){ref-type="supplementary-material"} and [S2D](#SD1){ref-type="supplementary-material"}). These analyses confirmed that the predominant turnover mode of H2B-FT-red is mediated by cell division. In these analyses, the half-life of H2B-FT-red (\~84 h in MEFs and \~37 h in HeLa cells) appeared longer than the 24 h half-life reported for the free FT-red ([@R68]). This gain in stability could result from fusion to a core histone, as histones are among the most stable proteins ([@R71]). These results indicate that the resolution of the H2B-FT as a cell cycle speed reporter could become limited in slow dividing cells, when non-division-mediated decay becomes too substantial to be ignored.

BR Responds to Cell Cycle Manipulation in Cultured Cells {#S5}
--------------------------------------------------------

To test whether cell cycle acceleration causes BR to increase as predicted by the model ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}; [Figures S1C](#SD1){ref-type="supplementary-material"} and [S1D](#SD1){ref-type="supplementary-material"}), we expressed c-Myc in primary MEFs carrying allelic expression of H2B-FT-medium (details below) ([Figure S1A](#SD1){ref-type="supplementary-material"}). After transduction with c-Myc or an empty vector (EV) control virus, H2B-FT fluorescence was quantified using time-lapse microscopy ([Figures S3A](#SD1){ref-type="supplementary-material"} and [S3B](#SD1){ref-type="supplementary-material"}). As expected, cells overexpressing c-Myc proliferated more rapidly ([Figure 3A](#F3){ref-type="fig"}). In agreement with the model, c-Myc-transduced MEFs had a higher BR than control MEFs after 70 h but not at 25 h post-transduction ([Figure 3B](#F3){ref-type="fig"}), which was presumably before the exogenously expressed c-Myc had significantly altered the cell cycle. Notably, BR was heterogeneous in both control and c-Myc cultures ([Figure 3C](#F3){ref-type="fig"}). To determine whether this reflected cell cycle speed heterogeneity, we classified cells on the basis of their relative BR using a flow cytometry-style gating strategy ([Figure 3C](#F3){ref-type="fig"}) and systematically determined individual cell cycle lengths by tracking the time interval between consecutive mitoses. In c-Myc cultures, there were more cells in the bluer group ("blue cells") and fewer red-gated cells ("red cells") ([Figures 3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}). Importantly, the blue cells divided faster than the red ones in both conditions ([Figure 3E](#F3){ref-type="fig"}). Whereas most red cells had a long cell cycle (\>30 h), the blue cell cycle length centered around 10--15 h in control MEFs and 5--10 h in c-Myc MEFs ([Figure 3E](#F3){ref-type="fig"}, blue cells). A small population (\~1.5%) of c-Myc cells had cell cycle lengths shorter than 5 h ([Figure 3E](#F3){ref-type="fig"}). Most cells with intermediate BR (cells between the gates in [Figure 3C](#F3){ref-type="fig"}) centered around 25 h/cycle, likely representing the gap between the fast cycling blue and the slow cycling red cells ([Figure 3E](#F3){ref-type="fig"}). These results concord with previous reports of MEF cell cycle length ([@R78]). Importantly, BR reflected cell cycle length regardless of whether cells had been transduced with c-Myc ([Figures 3E](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}).

The correspondence between short cell cycle and high BR supported the validity of H2B-FT as a cell cycle speed reporter and suggested that snapshot measurements by fluorescence microscopy could be used to estimate cell cycle length, which usually requires sophisticated long-term imaging and tracking with considerable phototoxicity ([@R63]). However, the fluorescence detection sensitivity by microscopy appeared limited, yielding a much narrower dynamic range compared with flow cytometry ([Figure S3C](#SD1){ref-type="supplementary-material"}). Therefore, quantitative estimation of cell cycle length was reserved for data acquired by flow cytometry, discussed below.

To test whether BR decreases upon cell cycle lengthening, we expressed H2B-FT in BaF3 cells, whose proliferation depends on IL-3 ([@R1]). BaF3 cells cultured in full IL-3 (270 pg/mL) proliferated rapidly, slowed proliferation within 48 h when IL-3 was reduced to 14 pg/mL, and completely ceased proliferation in IL-3-free conditions ([Figure 4A](#F4){ref-type="fig"}). Flow cytometry analysis of BR in these different growth conditions revealed that BaF3 cells grown in high IL-3 largely emitted blue fluorescence, which shifted toward the red axis at low IL-3 and became entirely red with IL-3 withdrawal ([Figure 4B](#F4){ref-type="fig"}; [Figures S3D](#SD1){ref-type="supplementary-material"} and [S3E](#SD1){ref-type="supplementary-material"}).

To facilitate direct comparison of flow cytometry data across diverse samples, we use a normalized BR, which is given by dividing a cell's blue signal intensity by its total blue and red intensity: $${\text{Normalized}\frac{\overline{B}}{\overline{R}} = \frac{\overline{B}}{\overline{B} + \overline{R}}}.$$ This normalization eliminates differences in the amount of H2B-FT protein expressed by individual cells and places all on a scale of 0--1, with 0 being all red and 1 being all blue ([Figures S4A](#SD1){ref-type="supplementary-material"}--[S4E](#SD1){ref-type="supplementary-material"}). All BR data were normalized in this manner. As expected, BaF3 BR decreased in response to cell cycle lengthening ([Figure 4C](#F4){ref-type="fig"}; [Figure S3E](#SD1){ref-type="supplementary-material"}). IL-3-induced differences in proliferation were captured by all three kinetic variants of the FT protein: H2B-FT-fast, H2B-FT-medium, and H2B-FT-slow ([Figures 4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}; [Figures S3D](#SD1){ref-type="supplementary-material"} and [S3E](#SD1){ref-type="supplementary-material"}). Furthermore, as predicted by the model ([Data S2](#SD1){ref-type="supplementary-material"}), the range of BR was lowest with FT-fast and highest with FT-slow ([Figures S3D](#SD1){ref-type="supplementary-material"} and [S3E](#SD1){ref-type="supplementary-material"}), which have the shortest and longest blue-to-red conversion times, respectively ([Figure S1A](#SD1){ref-type="supplementary-material"}). For simplicity, all data presented from here onward were obtained with H2B-FT-medium.

To examine the reporter's response to changes in cell cycle speed accompanying a cell fate transition, we expressed H2B-FT in mouse ESCs (mESCs) from a targeted allele ([@R33]) (details below and [Figure 4D](#F4){ref-type="fig"}) or by transposon ([@R31]). The characteristic mESC cell cycle of 8--10 h immediately lengthens upon differentiation ([@R78]). mESCs expressing H2B-FT were induced to differentiate with retinoic acid (RA) for 48 h ([@R79]) ([Figures S4F](#SD1){ref-type="supplementary-material"} and [S4G](#SD1){ref-type="supplementary-material"}), which slowed the cell cycle as confirmed by EdU/DAPI staining ([Figure 4E](#F4){ref-type="fig"}). As expected, RA-treated mESCs displayed a profound, population-wide shift toward the red axis ([Figure 4F](#F4){ref-type="fig"}). This brief RA treatment is expected to induce only partial differentiation, yielding cell state heterogeneity, which was captured by the prominently red-shifted but overlapping population following treatment ([Figure 4F](#F4){ref-type="fig"}; [Figures S4H](#SD1){ref-type="supplementary-material"} and [S4I](#SD1){ref-type="supplementary-material"}). Taken together, the two-color H2B-FT ratio responds to diverse modes of cell cycle manipulation in multiple cell types.

H2B-FT Enables Fluorescence-Activated Cell Sorting of Live Cells with Different Cycling Rates {#S6}
---------------------------------------------------------------------------------------------

To test the feasibility of physically separating live cells of distinct cell cycle rates, mESCs maintained in pluripotency conditions or treated with RA were sorted on the basis of BR ([Figures 4G](#F4){ref-type="fig"} and [4H](#F4){ref-type="fig"}). Cell cycle profiles of the sorted populations were confirmed by EdU/DAPI staining ([Figure 4I](#F4){ref-type="fig"}). As cells with longer cell cycles tend to increase their dwell time in G1 relative to other phases, slow dividing cells are expected to be enriched for G1 cells. Consistently, the reddest population ([Figures 4G](#F4){ref-type="fig"}--[4J](#F4){ref-type="fig"}, red) was enriched for G1 cells, while the bluest ([Figures 4G](#F4){ref-type="fig"}--[4J](#F4){ref-type="fig"}, blue) contained more G2/M cells. Cells from the middle FT gate ([Figures 4G](#F4){ref-type="fig"}--[4J](#F4){ref-type="fig"}, middle) had an intermediate cell cycle profile. These results are consistent with observations that mESCs do not respond homogeneously or synchronously to differentiation cues ([@R16]; [@R62]). Cell cycle rate heterogeneity was seen not only in the RA-treated samples but also in mESCs ([Figures 4G](#F4){ref-type="fig"}--[4J](#F4){ref-type="fig"}), corroborating reports that cellular heterogeneity exists under pluripotency maintenance conditions ([@R67]) and is often associated with the cell cycle ([@R21]; [@R23]).

To evaluate functional heterogeneity associated with the H2B-FT color profile, cells sorted from different BR gates were re-plated in pluripotency conditions to evaluate their ability to give rise to new colonies expressing the pluripotency marker alkaline phosphatase (AP) ([@R34]; [@R61]). We expected the slow cycling (red) cells to be more differentiated and have reduced colony-forming ability, and any cells remaining pluripotent during the RA treatment to be among the fastest cycling (blue) group. In concordance with the DAPI/EdU results, RA treatment greatly reduced overall colony-forming activity ([Figure 4K](#F4){ref-type="fig"}). Importantly, the residual colony-forming potential was most enriched in the blue cells and depleted in the red ones ([Figure 4K](#F4){ref-type="fig"}, right). Our results also demonstrated that even among cells never induced to differentiate, colony-forming potential was highest in the bluest cells, although this difference was less pronounced ([Figure 4K](#F4){ref-type="fig"}, left). These results confirmed the presence of cell cycle heterogeneity in both culture conditions, which could be prospectively separated by fluorescence activated cell sorting with the H2B-FT reporter.

The Proliferative Landscape of Live Hematopoietic Cells as Captured by H2B-FT {#S7}
-----------------------------------------------------------------------------

We harnessed the well-known proliferative differences among hematopoietic cells to test whether H2B-FT can report live-cell cycle speed *in vivo* ([@R55]). As a first approach, H2B-FT was virally introduced into donor hematopoietic stem and progenitor cells (HSPCs), which were transplanted into recipient mice. Following engraftment and reconstitution, we analyzed HSPCs defined as Lin−Kit+Sca1+ (LKS), GMPs, and whole bone marrow (WBM) ([Figures 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}; [Figures S5A](#SD1){ref-type="supplementary-material"} and [S5B](#SD1){ref-type="supplementary-material"}, gating strategy). The heterogeneity as reflected by the BR profile was most exaggerated in the WBM ([Figure 5B](#F5){ref-type="fig"}), consistent with the fact that it contains the entire dynamic spectrum from rapidly cycling progenitors to post-mitotic differentiated cells. In contrast, the GMP and LKS distributions were narrower ([Figure 5B](#F5){ref-type="fig"}). Among HSPCs positive for H2B-FT, LKS cells were red-shifted compared with GMPs ([Figures 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}), in agreement with the LKS compartment containing quiescent and slow cycling hematopoietic progenitors, while GMPs are highly proliferative ([@R55]; [@R80]). The reconstituted LKS cells were heterogeneous, containing a bluer subset ([Figures 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}) likely reflecting the more proliferative multipotent progenitors ([@R55]; [@R80]). Although the GMPs were collectively bluer than LKS and many other cells, they were not the bluest within the WBM ([Figure 5B](#F5){ref-type="fig"}). Further investigation revealed the bluest cells to be Ter119+ ([Figures 5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}), indicating erythroid identity ([@R36]). Contrastingly, Mac1+ myeloid cells displayed a wide BR distribution, with a severely red-shifted subpopulation ([Figures 5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}). Therefore, the proliferative behavior of hematopoietic cells, as established by BrdU uptake in fixed cells from earlier studies ([@R55]; [@R57]), can be conveniently recapitulated in live cells by the H2B-FT expressed from a viral vector.

To use the reporter in other tissues, we generated a knockin mouse by targeting the H2B-FT coding sequence into the universally active *HPRT* locus ([@R33]), under a Dox-inducible promoter (iH2B-FT) ([Figure 5E](#F5){ref-type="fig"}). When crossed with specific rtTA or tTA, H2B-FT can be induced in desired cell types. To test this mouse model and confirm the results from the viral system, we crossed the iH2B-FT allele with *Rosa26*::rtTA ([@R30]), which enables inducible H2B-FT expression in most tissues, including the hematopoietic system. The compound mice were healthy and fertile. To directly compare the proliferative behavior of erythroid progenitors (ProE) and GMPs, we pulsed the iH2B-FT mice with EdU for 2 h and analyzed the cell cycle profile of CD71+/Ter119+ cells and GMPs ([Figures S5A](#SD1){ref-type="supplementary-material"}--[S5C](#SD1){ref-type="supplementary-material"}, gating strategy). Approximately 40% of the erythroid cells, compared with 27% of GMPs, were EdU labeled ([Figure 5F](#F5){ref-type="fig"}). Accordingly, the CD71+/Ter119+ cells were further blue-shifted compared with GMPs ([Figure 5G](#F5){ref-type="fig"}), corroborating results obtained with the viral approach. The LKS compartment was again robustly red-shifted and heterogeneous ([Figure 5G](#F5){ref-type="fig"}), in agreement with virally expressed H2B-FT ([Figures 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}). Taken together, the known cycling rates of bone marrow cells are faithfully and reproducibly captured by the H2B-FT irrespective of expression strategy.

Peripheral blood mononucleocytes (PBMNs) primarily consist of B cells (B220+), T cells (CD3+), and neutrophils/monocytes (Mac1+) ([Figure 5H](#F5){ref-type="fig"}), with the myeloid cells turning over more rapidly than the lymphocytes ([@R55]). This difference was readily reflected by the H2B-FT: Mac1+ cells were bluer than B220+ or CD3+ cells, whose BR was highly heterogeneous ([Figure 5I](#F5){ref-type="fig"}, top). Although many circulating B and T cells did not express detectible H2B-FT, most myeloid cells (\>95%) were H2B-FT+ ([Figure 5I](#F5){ref-type="fig"}, top), on par with H2B-FT+ frequency in the WBM. Importantly, the H2B-FT+ B and T cells contained a severely red-shifted subpopulation, which could represent long-lived memory cells ([@R70]). Although the exact identity and function of these various cellular subsets remain to be studied, cell sorting with H2B-FT should provide a convenient methodology.

Last, we explored the iH2B-FT BR profile in a disease state characterized by overt proliferation, such as acute myeloid leukemia (AML). To induce AML, iH2B-FT mice were crossed with Dox-inducible MLL-ENL (iMLL-ENL) allele ([@R75]) and treated with Dox. As expected, the myeloid compartment expanded within 14 days, when the marrow contained a preponderance of L-GMPs ([Figure S5D](#SD1){ref-type="supplementary-material"}) and the blood became dominated by Mac1+ cells ([Figures 5H](#F5){ref-type="fig"} and [5I](#F5){ref-type="fig"}; [Figure S5E](#SD1){ref-type="supplementary-material"}, bottom). The expanded myeloid compartment was immediately visible by the increased number of H2B-FT+ cells in the unstained whole blood ([Figure 5I](#F5){ref-type="fig"}, bottom). Furthermore, the bluest shifted subpopulation became \~3 times larger than that in healthy control mice. Thus, the aberrant proliferative behaviors of malignant hematopoietic cells can be readily detected.

H2B-FT Unveils the Geography of Cell Proliferation *In Situ* {#S8}
------------------------------------------------------------

Because proliferation is compartmentally organized in many solid tissues, we evaluated the H2B-FT's ability to resolve such borders in frozen tissue sections. In mice pulsed with EdU for 35 min, we first examined the kidney, representing low homeostatic proliferation ([@R42]), and the pylorus, which contains rapidly cycling cells. The pylorus is a gastric glandular tube lined with epithelium supported by non-dividing nerve, blood vessel, and muscle cells ([@R72]). Gastric epithelial glands are organized into base, isthmus, and pit regions ([@R35]), with the most rapidly dividing progenitors located in the isthmus. As expected, the BR of kidney cells was much lower overall than that of the gastric epithelium ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}; [Figure S6](#SD1){ref-type="supplementary-material"}, top and middle). In contrast, the pylorus was heterogeneous, with a subset of cells appearing as red as the kidney ([Figure 6B](#F6){ref-type="fig"}, top and middle). When binned into five populations (P1--P5; [Figure 6B](#F6){ref-type="fig"}), BR was rendered into a pseudo-colored heatmap and applied back onto the original images ([Figures 6C](#F6){ref-type="fig"} and [6D](#F6){ref-type="fig"}). Notably, cells at the base of gastric glands were very red, juxtaposed abruptly with a region of bluer cells ([Figures 6A](#F6){ref-type="fig"} and [6C](#F6){ref-type="fig"}, middle). The co-localization of this color boundary with a dense band of EdU+ nuclei confirmed that the BR identified the border between the mostly quiescent base compartment and the transit-amplifying isthmus region. Glands that were fully captured longitudinally from base to pit further showed a declining BR past the most proliferative zone ([Figures 6C](#F6){ref-type="fig"} and [6D](#F6){ref-type="fig"}, "pylorus I"), as expected. Gastric glands captured in cross-section, representing assorted positions along the base-pit axis, showed the same co-localization between regions of high BR and high density of EdU+ cells ([Figures 6C](#F6){ref-type="fig"} and [6D](#F6){ref-type="fig"}, "pylorus II").

To test H2B-FT in embryogenesis, we examined the developing cortex, another tissue with well-recognized zones of proliferation and differentiation ([@R69]). Ventricular radial glia divide rapidly during corticogenesis, while their progeny undergo a limited number of fate-specifying cell divisions as they migrate away from the ventricular zone ([@R76]). In embryonic day (E) 17.5 iH2B-FT cortices, ventricular cells had the highest BR, followed by cells of the subventricular zone ([Figures 6A](#F6){ref-type="fig"}--[6C](#F6){ref-type="fig"}, bottom). Cells farther from the ventricle were redder, especially toward the interior of the brain. When tiled images are stitched together spanning a large tissue area, the H2B-FT color profile forms distinct layers in the embryonic cortex ([Figure 6E](#F6){ref-type="fig"}). The proliferative behavior revealed by H2B-FT confirms known developmental timelines ([@R11]) and again is supported by the location of EdU+ cells ([Figure 6C](#F6){ref-type="fig"}, bottom). For cells that exit cell cycle upon differentiation, the gradually decreasing BR should, up to a point, report relative time elapsed since their last division. Cells eventually plateau in their ability to become redder, reaching the resolution limit of the H2B-FT reporter. This is exemplified in the homogeneously red-shifted thalamus ([Figure 6E](#F6){ref-type="fig"}), in which new neuron production peaks at E14 but trails off by E17 ([@R11]). Therefore, BR reveals the distribution of relative cell cycle lengths *in situ* ([Figure 6F](#F6){ref-type="fig"}).

H2B-FT BR Provides an Estimate of Cell Cycle Length *In Vivo* {#S9}
-------------------------------------------------------------

Because the two-color H2B-FT ratio agreed with known proliferative behaviors across all biological settings tested, we sought to establish a workflow to quantify cell cycle length from BR obtained in single-time point measurements. The equation in [Data S2](#SD1){ref-type="supplementary-material"} describes a mathematical relationship between the steady-state BR,

$(\overline{B}/\overline{R})$, and the cell cycle length, *τ*~*D*~: $$\frac{\overline{B}}{\overline{R}} = \frac{C \cdot \tau_{C}}{\tau_{D}}.$$

$\overline{B}$ and $\overline{R}$ are quantified by fluorescence assays, preferably by flow cytometry given its high sensitivity ([Figure S3C](#SD1){ref-type="supplementary-material"}). The equation suggests that cell cycle length *τ*~*D*~ can be calculated as long as the constant *C* is known, as the color conversion time *τ*~*C*~ remains the same for a given FT variant ([Figure S1A](#SD1){ref-type="supplementary-material"}). The equation also states that *C τ*~*C*~ can be derived if *τ*~*D*~ can be experimentally determined. Therefore, we measured both cell cycle length distribution ([Figure 7A](#F7){ref-type="fig"}) and BR distribution ([Figure 7B](#F7){ref-type="fig"}) of the same cells using a combined live imaging/flow cytometry workflow. The details of the workflow to solve for *C*⋅ *τ*~*C*~ are described in the [Mathematical Appendix](#S26){ref-type="sec"} in [STAR Methods](#S11){ref-type="sec"} and in [Table S1](#SD1){ref-type="supplementary-material"}.

Having determined the value of *C τ*~*C*~ ([Figures 7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}), we entered this constant into the equation above to obtain cell cycle lengths for freshly isolated bone marrow cell types. Specifically, we assessed BR in mature monocytes and granulocytes (Gran) ([@R43]) as well as immunophenotypically defined stages of erythropoiesis ([@R39]) ([Figures S5F](#SD1){ref-type="supplementary-material"} and [S5G](#SD1){ref-type="supplementary-material"}, gating strategy). Gran were estimated to have a median cell cycle length of \>30 h. The ProE appeared to have the shortest median cell cycle, \~4.3 h ([Figure 7C](#F7){ref-type="fig"}). This result was particularly compelling, as it agrees with fetal liver ProE cell cycle length previously measured using sequential thymidine labeling ([@R32]). L-GMPs from iMLL-ENL mice had a wider range of cell cycle speeds than normal GMPs, with the median shifted toward a faster cell cycle of \~9 h/cycle ([Figure 7D](#F7){ref-type="fig"}). For most examined populations, cell cycle length distributions were similar across animals, and the variability generally decreased as the population became more immunophenotypically refined ([Figure 7E](#F7){ref-type="fig"}). High variability was seen in WBM, as expected for a heterogeneous tissue ([Figure 7E](#F7){ref-type="fig"}). However, the LKS compartment displayed striking variability across different animals ([Figure 7E](#F7){ref-type="fig"}), contrasting the uniformity of GMPs from the same cohort. Specifically, while GMPs had a median cell cycle length of \~11.6 ± 1.2 h across three mice, the median cell cycle length of the corresponding LKS compartment was 22.7, 28.3, and 36.1 h ([Figure 7F](#F7){ref-type="fig"}). We note that this median is most influenced by the predominant population, the more proliferative multipotent progenitors ([@R55]). The LKS compartment is known to be heterogeneous ([@R14]; [@R49]), fluctuates diurnally ([@R50]), remodels in response to injury ([@R26]), and evolves with aging ([@R4]; [@R40]). Our reporter reveals an unexpected level of heterogeneity across individuals even under homeostatic conditions, offering a unique tool for unveiling the role of HSPC heterogeneity in regeneration, aging, and disease.

DISCUSSION {#S10}
==========

Harnessing the distinct lifespans of the FT's two fluorescent states, we describe a novel, ratiometric method for resolving live-cell cycle length *in vitro*, *in vivo*, and *in situ*. Relative cell cycle speed can be determined from snapshot measurements by fluorescence imaging or flow cytometry: cellular BR faithfully reflects the proliferative state of all cell types tested, even in deep tissues inaccessible to imaging, making this a first-of-its-kind tool.

Measuring cell cycle length *in vivo* has previously been challenging and indirect. Detecting cell cycle dynamics in deep tissues relied largely on markers of specific cell cycle phases, such as the presence of EdU+ cells following a pulse label. Regions of EdU+ cells co-localize with areas of high BR ([Figures 6C](#F6){ref-type="fig"}--[6E](#F6){ref-type="fig"}), although cells marked by high BR are far less sparse. This is likely because EdU only marks cells that chanced to be in S phase during the pulse, leaving many blue (fast cycling) cells EdU−. Along with superior detection of fast cycling cells, BR also unveils hidden gradations in cell cycle length beyond the EdU+ zones. In general, interpreting pulse-label data assumes that S-phase duration varies minimally. In cases in which cell cycle accelerates by S-phase shortening ([@R32]), a fast cell cycle could (counterintuitively) present with decreased frequency of labeled cells. Conversely, a slow cycling population arrested at S phase could show increased labeling frequency. These shortcomings are partly remedied by sequential labeling with two thymidine analogs ([@R5]). However, the accuracy of the dual-labeling method requires a largely homogeneous population, as it calculates the mean cell cycle length of all cells analyzed. As BR is determined for each cell individually free of such assumptions, the H2B-FT reporter begins to unveil hidden cell cycle heterogeneity.

The H2B-FT reporter resolves cell cycle speed in a single snapshot, a distinguishing ability from cell cycle phase reporters ([@R58]). Besides revealing relative proliferation rate, BR can produce quantitative estimates of cell cycle length after a calibration step. Cell cycle length of ProE derived in this manner agree with results from dual thymine labeling ([@R32]). We note that the relationship between BR and cell cycle length is nonlinear ([Figure 1C](#F1){ref-type="fig"}). Experimental data from MEFs and briefly cultured GMPs, whose cell cycle length and BR can both be measured, support the model and show resolution plateauing beyond \~30 h/cycle ([Figure 3F](#F3){ref-type="fig"}; [Figure S7J](#SD1){ref-type="supplementary-material"}). Although flow cytometry can help extend this dynamic range owning to its superior sensitivity ([@R2]) ([Figure S3C](#SD1){ref-type="supplementary-material"}), this H2B-FT reporter is expected to better resolve faster cycling cells. For improved resolution at longer cell cycle lengths, future versions of the reporter could instead use the slow FT variant ([Figure S1A](#SD1){ref-type="supplementary-material"}; [Figures S3D](#SD1){ref-type="supplementary-material"} and [S3E](#SD1){ref-type="supplementary-material"}) or correct for BR "breathing" across the cell cycle ([Figure S1](#SD1){ref-type="supplementary-material"}) by simultaneous use of a phase reporter.

We anticipate wide use for H2B-FT as single-cell genomics underscore the importance of cellular heterogeneity, with cell cycle being a major driver ([@R3]; [@R53]). Expressed from a knockin allele, even rare cell types such as HSCs can be reliably analyzed ([Figures 5](#F5){ref-type="fig"} and [7](#F7){ref-type="fig"}). As the H2B-FT wavelengths are compatible with additional colors, this allele can be crossed with GFP-expressing reporters to further refine cells of interest. Unlike assays based on label dilution ([@R73]), H2B-FT's readout does not decay over cellular generations. We have also demonstrated that H2B-FT can be conveniently expressed, for example, by viral or transposon-based vectors, to enable cell cycle rate analysis in other models, including human cells. The ability to sort live cells free of additional labels or perturbation yields new opportunities to parse the interplay between cell fate regulation and cell cycle dynamics. For example, our previous work demonstrated the extraordinary response of naturally fast cycling GMPs (\~8 h/cell cycle) to pluripotency induction ([@R25]) and to malignancy initiation ([@R12]). Sorting the fastest cycling GMPs would allow an unprecedented look into a unique state of cellular plasticity. Further purification of HSPC subsets is under way given the remarkable heterogeneity seen in LKS cells ([Figure 7F](#F7){ref-type="fig"}). H2B-FT should also be helpful in the study of cell fate control during development. For example, it could pinpoint imbalances between proliferation and differentiation in the neocortex that may underlie neurodevelopmental disorders ([@R18]). Finally, the method described here should be applicable to questions of immediate clinical relevance, such as the functional differences between fast- and slow dividing cancer cells in terms of metastatic potential, therapy response, and immune evasion. When expressed specifically in the host, the H2B-FT could also dissect proliferation heterogeneity in the complex tumor niche ([@R47]; [@R64]).

Beyond its technical utility, the mathematical principles underlying the H2B-FT reporter have important biological implications. The experimental data depict a generalized relationship between molecular half-life and intracellular concentration. These findings constitute direct evidence for a mechanism by which cells can selectively alter their molecular contents by modulating cell cycle dynamics. Simplistically, intracellular molecules are placed in two categories: those existing long enough such that their intracellular concentration depends on cell cycle length and shorter lived molecules that are less sensitive to dilution by cell division. As these principles do not discriminate against any specific class of molecule, they suggest a fundamental mechanism by which cell cycle speed might be tuned to optimize the concentration of key molecular regulators, including proteins, their various post-translationally modified derivatives, RNA species, and others. This mode of regulation could echo direct regulation on the half-life of proteins and RNA, as their effective concentration is determined not only by their turnover rate but also by cell cycle length.

STAR★METHODS {#S11}
============

RESOURCE AVAILABILITY {#S13}
---------------------

### Lead Contact {#S14}

Requests for resources and further information should be directed to and will be fulfilled by the Lead Contact, Shangqin Guo (<shangqin.guo@yale.edu>).

### Materials Availability {#S15}

Submission of H2B-FT plasmids to Addgene is in process. iH2B-FT-Medium mice have been deposited to the Mutant Mouse Resource & Research Centers (MMRRC). Other unique materials generated in this study, including cell lines, are available from the authors upon request.

### Data and Code Availability {#S16}

No unique code was generated in this study. Raw data used to support the conclusions of this study are available from the authors on request. Custom CellProfiler ([@R7]) image analysis pipelines along with sample images are available on request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S17}
--------------------------------------

### Cloning and reporter cell lines {#S18}

pFast-FT-N1, pMedium-FT-N1, and pSlow-FT-N1 ([@R68]) were obtained from Addgene. Each FT coding sequence (\~711 bp each) was cloned into a Dox-inducible lentiviral backbone and a constitutive retroviral backbone. The inducible lentiviral plasmid (pFU-TetO-Gateway-PGK-Puro) was constructed previously ([@R24]) by inserting a Gateway cassette (Invitrogen), a PGK promoter, and a puromycin resistance gene into the pFU-tetO-Klf4 vector ([@R66]) through blunted EcoRI sites. Each FT insert was then cloned into this destination vector through Gateway recombination. For constitutive expression, the FT sequences were inserted into a pSCMV retroviral backbone ([@R24]) using HindIII and XhoI restriction sites. The H2B-FT fusion transgenes were constructed by overlap extension PCR using the three FT plasmids as well as the human H2B.J coding sequence from PGK-H2B-mCherry ([@R37], obtained from Addgene) as templates, and cloned into the pFU-TetO-Gateway-PGK-Puro and pSCMV expression plasmids. H2B-mCherry and H2B-BFP (BFP template obtained from Addgene) were similarly cloned to serve as single-color controls for the color-changing H2B-FT.

The MSCV-IRES-GFP ("empty vector") retroviral expression plasmid was previously described ([@R45]). The LZRS-c-Myc-IRES-GFP retroviral expression plasmid was a gift from Sebastian Nijman.

Viral vectors were transfected in 293T cells using Fugene® 6 transfection reagent (Promega). Viruses harvested from the supernatant were used to transduce BaF3 and HeLa cells. Successfully transduced cells were selected by fluorescence activated cell sorting.

*HPRT*::iH2B-FT knock-in mouse embryonic stem cells (mESCs) were generated using inducible cassette exchange (ICE) to target the TetO-CMV-H2B-FT transgene to the *HPRT* locus by cre-recombination in the A2lox.cre mESC cell line ([@R33]). Briefly, H2B-FT inserts (all three kinetic variants, [@R68] and [Figure S1A](#SD1){ref-type="supplementary-material"}), as well as H2B-BFP and H2B-mCherry were cloned into P2lox targeting plasmids ([@R33]) using HindIII and NotI restriction sites. The targeting plasmids were electroporated into Dox-activated A2lox.cre mESCs. After one day of recovery on neomycin-resistant feeder MEFs (Millipore Sigma), successfully recombined clones were selected by supplementing the mESC culture medium with 300μg/mL geneticin (G418, GIBCO). After 6 days of selection, healthy surviving colonies were hand-picked under an inverted microscope and replated onto C57BL/6J irradiated feeder MEFs. These "Passage 0" cultures were subsequently split for cryopreservation as well as continued culture and characterization of reporter activity by fluorescence microscopy and flow cytometry.

mESCs were made to constitutively express H2B-FT under an EF-1α promoter using the Sleeping Beauty transposon system ([@R31]). H2B-FT inserts (all three variants) were cloned into a modified empty transposon (pT3) backbone. A GFP sequence in the original backbone, pT3-Neo-EF1a-GFP ([@R13], obtained from Addgene), was replaced with a multiple cloning site (MCS) synthesized by IDT using MluI and NotI restriction cloning. The H2B-FT sequence was then inserted into the MCS using PmeI and NotI restriction sites. pT3-EF1a-H2B-FT vectors were transfected into C57BL/6J mESCs using Lipofectamine™ 2000 reagent (Invitrogen) along with a separate vector, pCMV(CAT)T7-SB100 ([@R48], obtained from Addgene), encoding the Sleeping Beauty transposase. Successfully transfected mESCs were enriched by fluorescence activated cell sorting.

Primer sequences used for cloning are provided in [Table S2](#SD1){ref-type="supplementary-material"}. Plasmid maps are available upon request.

### Cell culture and mESC differentiation {#S19}

MEFs, HeLa, and 293T cells were cultured in a standard growth medium ("MEF medium") consisting of DMEM basal medium (GIBCO) with 10% heat-inactivated fetal bovine serum (FBS) (GIBCO) and 1% penicillin/streptomycin/L-Glutamine supplement (Thermo Fisher Scientific). For MEF derivation from E13.5 embryos, this medium was additionally supplemented with 1% Non-essential amino acid (NEAA) mixture (Thermo Fisher Scientific) for the first passage *in vitro*. 293T cells used for viral transfection were cultured in the standard growth medium additionally supplemented with 1% sodium pyruvate (Thermo Fisher Scientific). Phenol-red-free Medium 199 (Thermo Fisher Scientific) was used in place of DMEM for live fluorescence microscopy experiments with H2B-FT HeLa cells ([Figure 2](#F2){ref-type="fig"}). Mouse embryonic stem cells (mESCs) were cultured either on γ-irradiated primary feeder MEFs or on plates coated with 0.1% gelatin in DMEM supplemented with 15% ESC-qualified FBS (Millipore Sigma), 1% penicillin/streptomycin/L-Glutamine, 1% NEAA, 1000U/ml LIF (Millipore Sigma), and 0.8μl/100mL β-mercaptoethanol. BaF3 cells were cultured in an RPMI-based growth medium consisting of 10% heat-inactivated FBS, 1% penicillin/streptomycin/L-Glutamine, and 270pg/mL IL-3 (Peprotech). Primary GMPs were cultured in x-vivo15 medium (Lonza) supplemented with 10% BSA (STEMCELL Technologies), 1% penicillin/streptomycin/L-Glutamine, 0.14μl/mL β-mercaptoethanol, and 100 ng/ml mSCF, 50 ng/ml mIL3, 50 ng/ml Flt3L, and 50 ng/ml mTPO (all from PeproTech).

*In vitro*, doxycycline (Sigma) was added to cell culture medium at 2μg/mL for inducible promoter activation. To induce iH2B-FT and/or iMLL-ENL expression *in vivo*, mice were fed drinking water containing 1g/L Dox supplemented with 10 g/L sucrose.

For the differentiation assay, mESCs maintained on feeder MEFs were transferred to feeder-free conditions (0.1% gelatin) for 2 passages to potentiate exit from pluripotency. The pluripotency of control cells was maintained with mESC culture medium, while the differentiation condition entailed switching the cells into standard MEF medium supplemented with 2μM retinoic acid (RA, Sigma).

For the colony recovery assay, sorted cells were plated onto feeder MEFs (n = 4 replicate wells) at a standardized seeding density and fed with mESC medium. After 6 days, the cultures were fixed and stained for alkaline phosphatase (AP) activity using the Stemgent AP II kit, in accordance with the protocol provided by the manufacturer. Culture wells were scanned under brightfield microscopy and colonies staining positive for AP activity were counted manually (RA treated group) or using MetaXpress® software automated image processing (mESCs).

Total mRNA was extracted with TRIzol® Reagent (Ambion) and reverse transcribed into cDNA using SuperScriptIII First-Strand Synthesis SuperMix (Invitrogen) according to the product manual. For quantitative real-time PCR, cDNA and gene-specific primers were mixed with iQ SYBR®Green Supermix (Bio-Rad) and carried out using a Bio-Rad CFX384 Real-Time PCR System. Gene expression levels were normalized to GAPDH level in the same sample. qPCR primer sequences are provided in [Table S2](#SD1){ref-type="supplementary-material"}.

### Mice {#S20}

All mouse work was approved by the Institutional Animal Care and Use Committee (IACUC) of Yale University. All research animals were housed and maintained in facilities of Yale Animal Resource Center (YARC).

*HPRT*::iH2B-FT-Medium chimeric mice were generated from passage 0 A2lox.cre H2B-FT targeted mouse embryonic stem cells by the Yale Genome Editing Center via blastocyst injection and implantation into C57BL/6J females. High-degree chimeric male offspring were selected by coat color and the iH2B-FT allele was subsequently crossed with mice carrying the *Rosa26*::rtTA allele ([@R30]), and backcrossed onto a C57BL/6J background. For all H2B-FT blue/red analysis of primary-harvested cells, H2B-FT expression was induced *in vivo* for at least one week by feeding Dox drinking water. Tissues from iH2B-FT mice were harvested and analyzed when the mice were 8--12 weeks of age. For experiments involving AML induction, iH2B-FT mice were crossed with iMLL-ENL mice ([@R75]), and offspring were harvested at 5 weeks old. All cohorts reported here involved male mice. Genotyping primer sequences are provided in [Table S2](#SD1){ref-type="supplementary-material"}.

Primary feeder MEFs for pluripotent stem cell culture were derived from C57BL/6J (Jackson Laboratory) E13.5 mouse embryos and mitotically inactivated by 80 Gy γ-irradiation. H2B-FT-Medium MEFs were derived from *HPRT*::iH2B-FT-Medium E13.5 mouse embryos.

METHOD DETAILS {#S21}
--------------

### HSPC transplantation {#S22}

Bone-marrow-derived LKS (Lineage-/Kit+/Sca-1+) cells from homozygous *Rosa26*::rtTA male donor mice were isolated by fluorescence activated cell sorting and transduced overnight *in vitro* with TetO-H2B-FT lentivirus and injected through the tail vein at \> 10,000 cells/mouse into 9-week-old female C57BL/6J mice (Jackson Laboratory) γ-irradiated recipient mice (9 Gy) along with 500,000 WBM support cells. Alternatively, donor mice were injected intraperitoneally with 150μg/g body weight 5-fluorouracil (5-FU, APP Pharmaceuticals, LLC) 4 days before harvesting, and the HSPC-enriched WBM was virally transduced and then transplanted at a ratio of 1 donor per 2 recipients. Transplanted mice were given a one-time intraperitoneal injection of 200μg Dox and thereafter continuously maintained on Dox drinking water. After four weeks, peripheral blood was collected and analyzed by flow cytometry to evaluate H2B-FT expression coming from the engrafted virally transduced cells. Bone marrow HSPCs were harvested between 8--16 weeks post-transplantation and stained with fluorescent antibodies marking Lineage, Kit, Sca-1, CD34, and CD16/32. "Lineage" refers to a cocktail of antibodies included biotin-conjugated Ter119, CD3e, CD4, CD8, CD11b, Gr1, and B220. Cellular fluorescence was recorded on an LSRII flow cytometer (BD) or a FACSAria cell sorter (BD) using FACSDiva software (BD), and the data were subsequently analyzed using FlowJo software (FlowJo, LLC).

All antibodies used in this study are listed in the [Key Resources Table](#T1){ref-type="table"}.

### EdU/DAPI labeling {#S23}

Cultured cells were treated with growth medium containing 10μM EdU (5-ethynyl-2′-deoxyuridine) for 15 minutes. EdU was rinsed away with PBS and cells were trypsinized into a single-cell suspension for immediate fixation or H2B-FT blue/red fluorescence activated cell sorting followed by fixation. For *in vivo* labeling of adult tissues, mice were pulsed with EdU at 50μg/g body weight via intraperitoneal injection either 2 hours ([Figure 5F](#F5){ref-type="fig"}) or 35 minutes ([Figure 6](#F6){ref-type="fig"}) before harvesting. Pregnant dams were given EdU intravenously at 50μg/g body weight 35 minutes before harvesting embryos ([Figure 6](#F6){ref-type="fig"}, E17.5 cortex).

H2B-FT-blue and red signal was captured (by flow cytometry or microscopy) in unfixed cells/tissue prior to downstream steps, as exposure to fixative prematurely converts blue molecules into red.

Labeling in suspension: Bone-marrow-derived HSPCs plus Ter119+ cells were enriched via streptavidin-conjugated magnetic microbead separation (Miltenyi Biotec) of Lineage+ cells (this Lineage cocktail included biotin-conjugated CD3e, CD4, CD8, CD11b, Gr1, and B220); stained with GMP markers or CD71/Ter119; and sorted on a FACSAria (BD) directly into 70% ethanol. These fixed single-cell suspensions of EdU-treated cells were stored in 70% ethanol at −20C for \> 24h, and then rinsed in PBS. Cells were permeablized in 0.2% Triton X-100 in PBS at room temperature for 15 minutes and then fluorescently labeled by Click chemistry using a Click-IT EdU-488 kit (Thermo Fisher Scientific) for 30 minutes at room temperature in an AF488-azide EdU labeling cocktail prepared according to the product manual. Cells were rinsed in PBS and incubated for 10 minutes at room temperature in 1μg/mL DAPI (Thermo Fisher Scientific) diluted in PBS. Cells were rinsed once more with PBS and resuspended in a PBS buffer containing 1% BSA, then analyzed by flow cytometry on a BD LSRII.

Labeling on slides: Intact organs (kidney, stomach) and whole embryos were embedded in cryomolds (Sakura) filled with OCT compound (Sakura), and flash-frozen in a 2-methylbutane/liquid nitrogen bath. 5μm sections were cut at −25C using a CM3050 S cryostat (Leica) and mounted onto SuperFrost® slides (Fisher Scientific). Frozen sections were scanned by fluorescence microscopy (details below) at 20x to capture blue and red H2B-FT signal, and then slides were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 12 minutes at room temperature. Samples were washed, permeablized, and stained as described above.

### Microscopy {#S24}

Live- and fixed-cell microscopy was performed using a Molecular Devices ImageXpress® Micro 4 high-throughput compound inverted epifluorescence microscope equipped with a live imaging environment. For time-lapse imaging, cells were plated into a Greiner Bio-One CellStar® 96well plate, sealed with a Breathe-Easy® gas-permeable membrane, and maintained at 37C/5% CO2 for the duration of the experiment. MetaXpress® 6 software was used for all image acquisition and for some image processing and analysis. Most of the image segmentation and image-based measurements were carried out using CellProfiler ([@R7]) and exported into FCS Express 6 Image Cytometry software (*De Novo* Software) for data analysis. ImageJ software ([@R59]) was used for some image processing.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S25}
---------------------------------------

### Mathematical Appendix {#S26}

This appendix describes the details of cell cycle length quantification from the BR readout of the H2B-FT reporter. A comprehensive list of experimental considerations for acquiring BR data is provided in [Table S1](#SD1){ref-type="supplementary-material"}.

### Determining the equation constant {#S27}

[Data S2B](#SD1){ref-type="supplementary-material"} describes a mathematical relationship between the steady-state BR, $(\overline{B}/\overline{R})$, and the cell cycle length, *τ*~*D*~: $$\frac{\overline{B}}{\overline{R}} = \frac{C \cdot \tau_{C}}{\tau_{D}}$$ where *τ*~*C*~ is the time required for the molecular conversion of blue to red, and*C*is a normalization constant. Because $\overline{B}$ and $\overline{R}$ are readily quantified in a fluorescence assay, the equation suggests that the cell cycle length *τ*~*D*~ can be calculated if the constant *C* can be experimentally determined, as the color conversion time *τ*~*C*~ remains the same for a given FT variant ([Figure S1A](#SD1){ref-type="supplementary-material"}). With the $(\overline{B}/\overline{R})$ value normalized to the total cellular FT content, $\overline{B} + \overline{R}$, the modified equation then becomes: $$\frac{\overline{B}}{\overline{B} + \overline{R}} = \frac{C \cdot \tau_{C}}{C \cdot \tau_{C} + \tau_{D}}$$

We found that C depended on the fluorescence detection parameters: exposure time in the case of fluorescence microscopy, and laser voltage for flow cytometry ([Figures S7A](#SD1){ref-type="supplementary-material"}--[S7E](#SD1){ref-type="supplementary-material"}). To determine the value of *C*, we directly measured the cell cycle lengths of iH2B-FT GMPs during a 24h culture period by live-cell imaging and single-cell tracking ([Figure 7A](#F7){ref-type="fig"}). After 24h, the imaged iH2B-FT GMPs were analyzed by flow cytometry to determine their BR profile ([Figure 7B](#F7){ref-type="fig"}). Thus, the BR distribution for these 24h cultured cells could be matched to their directly observed cell cycle speed distribution. This provided paired coordinate values for $(\overline{B}/\overline{B} + \overline{R})$ and cell cycle length *τ*~*D*~ such that the value of the combined constant *C τ*~*C*~ could be calculated ([Figures S7F](#SD1){ref-type="supplementary-material"} and [S7G](#SD1){ref-type="supplementary-material"}). Separate calculations were performed using coordinates representing the 10^th^, 25^th^, 50^th^ and 80^th^ percentile of cell cycle length, assumed to correspond to the 90^th^, 75^th^, 50^th^ and 20^th^ percentile of the bluest cells, respectively ([Figure S7G](#SD1){ref-type="supplementary-material"}). Within the examined cell cycle speed range, these calculated cell cycle values differed maximally from observed values by 2.06h at the 10th percentile and 6.25h at the 80th percentile ([Figure S7G](#SD1){ref-type="supplementary-material"}). Predictions 2 and 3 were closest to observed cell cycle lengths, differing at most by 1.17h and 3.43h at the 10th and 80th percentiles, respectively ([Figure S7G](#SD1){ref-type="supplementary-material"}). The resulting C ∙ τC values were then plugged back into the equation ([Figure S7F](#SD1){ref-type="supplementary-material"}) to produce curves which we evaluated for their similarity to each other, and to the experimental microscopy data ([Figure S7H](#SD1){ref-type="supplementary-material"}). Based on the plot in [Figure S7H](#SD1){ref-type="supplementary-material"}, a *C τ*~*C*~ value representing the average of predictions 2 and 3 was selected for estimating *in vivo* cell cycle lengths.

### Considering mitosis-independent red decay {#S28}

As H2B-FT-red does exhibit decay independent of cell division in MEFs and HeLa cells ([Figure S2](#SD1){ref-type="supplementary-material"}), we considered a modified version of the equation shown in [Data S2](#SD1){ref-type="supplementary-material"} in which a rate constant for active degradation, τ~R~, was incorporated into the red removal rate, δ ([Figure S7I](#SD1){ref-type="supplementary-material"}): $$\delta = \frac{1}{\tau_{R}} + \frac{1}{\tau_{D}}$$

However, as the exact red degradation parameter in hematopoietic cells *in vivo* is unknown, we examined the relationship between BR and cell cycle length by modeling a wide range of red decay rates ([Figures S7J](#SD1){ref-type="supplementary-material"} and [S7K](#SD1){ref-type="supplementary-material"}). These exercises showed that for cell cycle lengths shorter than 30h, the red degradation rate was irrelevant; there was little difference in cell cycle lengths whether H2B-FT-red was assumed to be shorter (35h) or longer (135h), or whether it was simply ignored ((1 /*τ*~*R*~)→0), when δ becomes simply inversely proportional to τ~D~ as in [Data S2B](#SD1){ref-type="supplementary-material"}. At longer cell cycle lengths (\> 30h), ignoring red decay resulted in the shortest possible prediction of cell cycle length for a given BR value, while incorporating red decay adjusted these predictions upward in a manner inversely correlated with half-life ([Figures S7J](#SD1){ref-type="supplementary-material"} and [S7K](#SD1){ref-type="supplementary-material"}). To visualize these different scenarios in our actual bone marrow data, we proceeded to generate two estimates of cell cycle length with different red decay parameters: either by ignoring cell division-independent decay or by setting the red fluorescence half-life to 85h ([Figure S7L](#SD1){ref-type="supplementary-material"}). Although absolute cell cycle length for slow-dividing cells remains more uncertain than in fast-cycling cells, the relative differences between cell types are still maintained in any version of the equation. Therefore, in order to compare cell cycle length distributions across many hematopoietic cell types and different individual mice ([Figures 7C](#F7){ref-type="fig"}--[7F](#F7){ref-type="fig"}), we chose the simplest version of the equation (red decay ignored) for reporting results, while acknowledging that slow cell cycle lengths (\> 30h) are likely to be underestimated using this assumption.

With these considerations and having determined the value of *C τ*~*C*~, we proceeded to estimate the cell cycle length distributions for various hematopoietic cell types ([Figure 7C](#F7){ref-type="fig"}).

### Statistical Analysis {#S29}

Details pertaining to each statistical analysis are provided in the figure legend accompanying the relevant data figure. All statistical tests used were two-tailed and were carried out using Prism software (GraphPad). All measurements were taken from distinct samples.
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![Design Principles of a Fluorescent Reporter of Cell Cycle Speed\
(A) On the basis of the equation in [Data S1](#SD1){ref-type="supplementary-material"}, intracellular levels of a molecule (*M*) depend on its half-life and cell cycle length. The ratio of *M*'s concentration in theoretical cells of different cycling speeds is plotted. When *M* is short lived (circle, far left), its concentration shows little difference between slow and fast cycling cells. With long-lived M (circle, far right), the concentration difference increases in proportion to the difference in cell cycle lengths.\
(B) The fluorescent timer (FT) is short lived as a blue protein and long lived as a red protein.\
(C) The average blue/red ratio (BR) of cells expressing FT drops as cell cycle lengthens (see [Data S2](#SD1){ref-type="supplementary-material"}). Because BR fluctuates within a cell cycle (see [Figure S1](#SD1){ref-type="supplementary-material"}), the relationship between BR and cell cycle length is best described by a probability distribution. For modeling, cells are assumed to maintain a constant cycling rate. Solid and dashed error bars denote 1 and 2 SDs, respectively.\
(D) Anticipated positions of slow and fast asymmetrically cycling cells on a hypothetical plot of blue versus red fluorescence.](nihms-1607448-f0002){#F1}

![Characterization of the H2B-FT Reporter in Cultured Cells\
(A) The inducible H2B-FT expression construct.\
(B) HeLa cells expressing H2B-FT.\
(C) Time series of H2B-FT fluorescence in HeLa cells after Dox induction.\
(D and E) Quantification of average nuclear blue (D) and red (E) FT intensity over time following Dox treatment.\
(F) Time series of HeLa cells after Dox washout at T = 4.5 h.\
(G) BR over time following Dox treatment. Error bars represent SD across n = 3 culture wells. Scale bars, 50 μm.](nihms-1607448-f0003){#F2}

![H2B-FT Color Profile Reflects Cell Proliferation Rate *In Vitro*\
(A) Proliferation of H2B-FT MEFs after transduction with c-Myc or empty vector control (EV). Error bars: SD across n = 4 culture wells.\
(B) Cellular BR at 25 and 70 h post-transduction. Box plots represent median and interquartile range (IQR); whiskers, 5th--95th percentiles. p = 0.295 (25 h) and p \< 0.0001 (70 h) on the basis of Mann-Whitney test with 99% confidence interval (CI).\
(C) Representative blue versus red intensity of individual cells at 70 h post transduction. Flow cytometry-style gates define "red" and "blue" populations (see also [Figures S3A](#SD1){ref-type="supplementary-material"} and [S3B](#SD1){ref-type="supplementary-material"}).\
(D) Percentage of cells within gates defined in (C). Percentages do not total 100%, as many cells lie between red and blue gates. Error bars show SD across n = 4 culture wells. p = 0.0035 (red cells) and p = 0.0498 (blue cells) on the basis of Student's t test with Welch's correction, 95% CI. dF = 4.057 (red cells) and dF = 3.221 (blue cells).\
(E) Cell cycle length distributions in each gate as measured by image-based tracking. Cell cycle length refers to the time interval between consecutive mitoses.\
(F) Correlation between cell cycle length and BR. All trackable cells (n = 220) from c-Myc and EV conditions are plotted. Spearman correlation coefficient = 0.7648; p \< 0.0001 with 95% CI.\
n values in (B) and (E) refer to the numbers of single cells analyzed.](nihms-1607448-f0004){#F3}

![H2B-FT Enables Fluorescence-Activated Cell Sorting of Live Cells with Different Proliferative Rates\
(A) BaF3 proliferation in varying IL-3 concentrations. Error bars: SD across n = 6 culture wells.\
(B) Representative flow cytometry plots of BaF3 cells expressing H2B-FT-medium, grown as in (A).\
(C) Density plots of BR derived from flow cytometry data in (B).\
(D) H2B-FT knockin mESCs. Scale bar, 80 μm. Full-size image shown in [Data S3A](#SD1){ref-type="supplementary-material"}.\
(E) DAPI/EdU cell cycle profile after 48 h RA treatment.\
(F) Representative flow cytometry plots of pluripotent and RA-treated mESCs (top). Cells not exposed to Dox served as colorless control to demarcate H2B-FT+ gate. Data were rendered into BR density plots (bottom).\
(G and H) Pluripotent and RA-treated mESCs stably expressing H2B-FT via Sleeping Beauty transposon were sorted on the basis of BR using the gating strategy shown. Non-transfected mESCs (gray) served as colorless control. (G) Representative FACS plots and gating. (H) Quantification of BR.\
(I) DAPI/EdU cell cycle profiles of sub-populations sorted as in (G).\
(J) Percentage of cells in G1 versus G2/M from the sorted populations in (G).\
(K) Number of AP+ colonies recovered per 8,000 cells sorted in (G) after 6 day culture. Error bars: SD across n = 3 or 4 culture wells. p \< 0.001, one-way ANOVA, dF = 3.\
See also [Figures S3D](#SD1){ref-type="supplementary-material"}, [S3E](#SD1){ref-type="supplementary-material"}, and [S4](#SD1){ref-type="supplementary-material"}.](nihms-1607448-f0005){#F4}

![The Proliferative Landscape of Live Hematopoietic Cells as Captured by the H2B-FT Reporter\
(A) Representative flow cytometry plots of LKS and GMP cells from mouse BM reconstituted by HSPCs virally expressing H2B-FT.\
(B) Data from (A) plotted as BR distribution, with WBM BR added.\
(C) Flow cytometry plots of myeloid (Mac1+) and erythroid (Ter119+) cells from the mouse in (A) and (B).\
(D) BR distribution of data in (C). Gates in (A) and (C) excluded the non-transduced (H2B-FT−) cells.\
(E) Targeting strategy for the iH2B-FT mouse allele.\
(F) DAPI/EdU profiles of GMPs versus early erythroid cells after 2 h EdU labeling *in vivo*.\
(G) BR distributions in LKS, GMPs, and early erythroid cells.\
(H) Percentage of myeloid (Mac1+), B cell (B220+), and T cell (CD3+) cells in peripheral blood of healthy iH2B-FT mice versus those crossed with MLL-ENL (n = 3 mice per group). All mice were treated with Dox ≥8 days prior to analysis. Error bars represent SD; p = 0.0090 (Mac1+), p = 0.0072 (B220+), and p = 0.7629 (CD3+) on the basis of Student's t test with 95% CI, dF = 4.\
(I) Representative BR profiles of the PBMN subsets in (H).](nihms-1607448-f0006){#F5}

![H2B-FT Profile Is Consistent with Relative Turnover Rates in Solid Tissue Sections\
(A) H2B-FT appearance in representative frozen sections from adult and embryonic iH2B-FT mice. Top: kidney. Middle: gastric glands in two orientations, longitudinal (pylorus I) and oblique/cross-sectional (pylorus II). L, lumen; S, submucosa. Bottom: neocortex of an E17.5 embryo. Dotted line indicates lateral ventricle (LV). See [Figure S6](#SD1){ref-type="supplementary-material"} for single-channel images.\
(B) BR histogram for each image in (A) was subdivided into five populations of increasing BR (P1--P5).\
(C) Left, a heatmap corresponding to P1--P5 in (B) projected onto images from (A). Right: the same regions after DAPI/EdU labeling.\
(D) Zoomed-in view of pyloric regions boxed in (C). Arrow: base of a gastric gland.\
(E) Tiled images of an E17.5 embryonic brain hemisphere. Left: H2B-FT. Middle: heatmap of BR binned as in (B). Right: same region after DAPI/EdU labeling. Dotted line indicates LV. IZ, intermediate zone; CP, cortical plate; MZ, marginal zone; Th, thalamus.\
(F) BR distributions from all tissues in (A). "Pylorus" includes combined data from both orientations (pylorus I and II, A).\
Scale bars, 200 μm (A and C), 80 μm (D), and 500 μm (E). Full-size images are shown in [Data S3B](#SD1){ref-type="supplementary-material"}--[S3H](#SD1){ref-type="supplementary-material"}.](nihms-1607448-f0007){#F6}

![Estimating *In Vivo* Cell Cycle Length from H2B-FT BR\
(A and B) Cell cycle length distribution of n = 215 GMPs determined by time-lapse microscopy and BR distribution as analyzed by flow cytometry. Dotted lines show indicated percentiles.\
(C) Calculated cell cycle length distributions of BM populations from a representative iH2B-FT mouse.\
(D) Cell cycle length distribution of L-GMPs driven by MLL-ENL versus normal GMPs.\
(E) Median cell cycle length variation among n = 3 iH2B-FT mice, shown by percentage coefficient of variation (CV%).\
(F) Cell cycle length distributions of LKS and GMP from the individual mice in (E).\
Boxes in (C), (D), and (F) represent median and IQR of each group; whiskers, 5th--95th percentiles. See also [Figure S7](#SD1){ref-type="supplementary-material"}.](nihms-1607448-f0008){#F7}

  REAGENT or RESOURCE                                                                                               SOURCE                                                    IDENTIFIER
  ----------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- -----------------------------------
  Antibodies                                                                                                                                                                  
  Biotin rat anti-mouse Ly-6G/6C Clone RB6-8C5                                                                      BD Biosciences                                            Cat\#553125; RRID:AB_394641
  Biotin hamster anti-mouse CD3e Clone 145-2C11                                                                     BD Biosciences                                            Cat\#553060; RRID:AB_394593
  Biotin rat anti-mouse CD45R/B220 Clone RA3-6B2                                                                    BD Biosciences                                            Cat\#553086; RRID:AB_394616
  Biotin rat anti-mouse CD11b Clone M1/70                                                                           BD Biosciences                                            Cat\#553309; RRID:AB_394773
  Biotin rat anti-mouse Ter119                                                                                      BD Biosciences                                            Cat\#553672; RRID:AB_394985
  Biotin rat anti-mouse CD8a Clone 53-67                                                                            BD Biosciences                                            Cat\#553029; RRID:AB_394567
  Biotin rat anti-mouse CD4 Clone GK1.5                                                                             BD Biosciences                                            Cat\#553728; RRID:AB_395012
  APC rat anti-mouse CD117 Clone 2B8                                                                                BD Biosciences                                            Cat\#553356; RRID:AB_398536
  FITC rat anti-mouse Ly6A/E (Sca-1) Clone E13-161.7                                                                BD Biosciences                                            Cat\#553335; RRID:AB_394791
  PerCP Streptavidin                                                                                                BD Biosciences                                            Cat\#554064; RRID:AB_2336918
  PE-Cy7 rat anti-mouse CD16/32 Clone 93                                                                            Thermo Fisher Scientific                                  Cat\#25-0161-82; RRID:AB_469598
  Alexa Fluor rat 700 anti-mouse CD34 Clone RAM34                                                                   BD Biosciences                                            Cat\#560518; RRID:AB_1727471
  APC rat anti-mouse CD11b Clone M1/70                                                                              Thermo Fisher Scientific                                  Cat\#17-0112-83; RRID:AB_469344
  FITC rat anti-mouse CD45R/B220 Clone RA3-6B2                                                                      BD Biosciences                                            Cat\#553087; RRID:AB_394617
  PE-Cy7 rat anti-mouse CD3 Clone 17A2                                                                              BioLegend                                                 Cat\#100219; RRID:AB_1732068
  FITC rat anti-mouse CD71 Clone C2                                                                                 BD Biosciences                                            Cat\#553266; RRID:AB_394743
  PE-Cy7 rat anti-mouse Ter119                                                                                      Thermo Fisher Scientific                                  Cat\#25-5921-81; RRID:AB_469660
  FITC rat anti-mouse Ly6C Clone AL-21                                                                              BD Biosciences                                            Cat\#553104; RRID:AB_394628
  PE-Cy7 rat anti-mouse Ly6G Clone 1A8                                                                              BD Biosciences                                            Cat\#560601; RRID:AB_1727562
  Streptavidin MicroBeads                                                                                           Miltenyi Biotec                                           Cat\#130-048-101
  Bacterial and Virus Strains                                                                                                                                                 
  pFast-FT-N1                                                                                                       Dr. Vladislav Verkhusha ([@R68])                          RRID:Addgene_31910
  pMedium-FT-N1                                                                                                     Dr. Vladislav Verkhusha ([@R68])                          RRID:Addgene_31911
  pSlow-FT-N1                                                                                                       Dr. Vladislav Verkhusha ([@R68])                          RRID:Addgene_31912
  pFU-TetO-Gateway-PGK-Puro                                                                                         Dr. Jun Lu ([@R24])                                       N/A
  pSCMV                                                                                                             Dr. Jun Lu ([@R24])                                       N/A
  PGK-H2B-mCherry                                                                                                   Dr. Mark Mercola ([@R37])                                 RRID:Addgene_21217
  pMSCV-IRES-Blue FP                                                                                                Dr. Dario Vignali                                         RRID:Addgene_52115
  MSCV-IRES-GFP                                                                                                     Dr. Jun Lu ([@R45])                                       N/A
  LZRS-c-Myc-IRES-GFP                                                                                               Dr. Sebastian Nijman                                      N/A
  pFU-TetO-H2B-FT-Fast-PGK-Puro                                                                                     This Publication                                          N/A
  pFU-TetO-H2B-FT-Medium-PGK-Puro                                                                                   This Publication                                          N/A
  pFU-TetO-H2B-FT-Slow-PGK-Puro                                                                                     This Publication                                          N/A
  pSCMV-H2B-FT-Fast                                                                                                 This Publication                                          N/A
  pSCMV-H2B-FT-Medium                                                                                               This Publication                                          N/A
  pSCMV-H2B-FT-Slow                                                                                                 This Publication                                          N/A
  p2Lox                                                                                                             Dr. Michael Kyba ([@R33])                                 RRID:Addgene_34635
  pT3-Neo-EF1a-GFP                                                                                                  Dr. Martin Bonamino ([@R13])                              RRID:Addgene_69134
  pCMV(CAT)T7-SB100                                                                                                 Dr. Zsuzsanna Izsvak ([@R48])                             RRID:Addgene_34879
  pT3-EF1a-H2B-FT-Fast                                                                                              This Publication                                          N/A
  pT3-EF1a-H2B-FT-Medium                                                                                            This Publication                                          N/A
  pT3-EF1a-H2B-FT-Slow                                                                                              This Publication                                          N/A
  Biological Samples                                                                                                                                                          
  Primary neomycin resistant feeder MEFs, Mitomycin C treated                                                       Millipore Sigma                                           Cat\#PMEF-N
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                               
  ESGRO mLif Medium Supplement                                                                                      Millipore Sigma                                           Cat\#ESG1107
  Recombinant murine IL-3                                                                                           PeproTech                                                 Cat\#213-13
  Recombinant murine SCF                                                                                            PeproTech                                                 Cat\#250-03
  Recombinant murine TPO                                                                                            PeproTech                                                 Cat\#315-14
  Recombinant human Flt3 Ligand                                                                                     PeproTech                                                 Cat\#300-19
  Doxycycline hyclate                                                                                               Sigma Aldrich                                             Cat\#D9891; CAS ID 24390-14-5
  Retinoic acid                                                                                                     Sigma Aldrich                                             Cat\#R2625; CAS ID 302-79-4
  DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride)                                                             Thermo Fisher Scientific                                  Cat\#D1306; RRID:AB_2629482
  EdU (5-Ethynyl-2′-deoxyuridine)                                                                                   Cayman Chemical                                           Cat\#20518; CAS ID 61135-33-9
  5-FU (5-Fluorouracil)                                                                                             APP Pharmaceuticals, LLC                                  NDC 63323-117-10
  Critical Commercial Assays                                                                                                                                                  
  Molecular Probes Click-iT Plus EdU Alexa Fluor 488 Imaging Kit Cat\# C10637                                       Thermo Fisher Scientific                                  Cat\#C10637
  Stemgent AP Staining Kit II                                                                                       REPROCELL                                                 Cat\#00-0055
  SuperScript III First-Strand Synthesis SuperMix                                                                   Thermo Fisher Scientific                                  Cat\#18080400
  iQ SYBR Green Supermix                                                                                            Bio-Rad                                                   Cat\#170-8882
  MACS LD Columns                                                                                                   Miltenyi Biotec                                           Cat\#130-042-901
  QuadroMACS Separator                                                                                              Miltenyi Biotec                                           Cat\#130-090-976
  MACS MultiStand                                                                                                   Miltenyi Biotec                                           Cat\#130-042-303
  Experimental Models: Cell Lines                                                                                                                                             
  HEK293T Cell Line                                                                                                 ATCC                                                      Cat\#CRL-3216; RRID:CVCL_0063
  HeLa Cell Line                                                                                                    ATCC                                                      Cat\#CRM-CCL-2; RRID:CVCL_0030
  BaF3 Cell Line                                                                                                    RCB                                                       Cat\#RCB0805; RRID:CVCL_0161
  A2lox.cre mESC Cell Line                                                                                          Dr. Michael Kyba ([@R33])                                 N/A
  A2lox.cre H2B-FT-Fast mESC Cell Line                                                                              This Publication                                          N/A
  A2lox.cre H2B-FT-Medium mESC Cell Line                                                                            This Publication                                          N/A
  A2lox.cre H2B-FT-Slow mESC Cell Line                                                                              This Publication                                          N/A
  A2lox.cre H2B-BFP mESC Cell Line                                                                                  This Publication                                          N/A
  A2lox.cre H2B-mCherry mESC Cell Line                                                                              This Publication                                          N/A
  Experimental Models: Organisms/Strains                                                                                                                                      
  *Mus musculus*: *HPRT*::iH2B-FT-Medium: B6.Cg- Gt(ROSA)26Sor^tm1(rtTA\*M2)Jae^ Hprt^tm2(tetO-H2B/mediumFT)Sguo^   This Publication                                          MMRRC Cat\#66959
  *Mus musculus*: iMLL-ENL: Col1a1^tm1(tetO-KMT2A/ELL)Dbry^                                                         Dr. David Bryder ([@R75])                                 MGI ID 5825211
  *Mus musculus*: *Rosa26*::rtTA: Gt(ROSA) 26Sor^tm1(rtTA\*M2)Jae^                                                  Jackson Laboratory                                        Cat\#006965; RRID:IMSR_JAX:006965
  *Mus musculus*: C57BL/6J                                                                                          Jackson Laboratory                                        Cat\#000664; RRID:IMSR_JAX:000664
  Oligonucleotides                                                                                                                                                            
  Primers for cloning                                                                                               See [Table S2](#SD1){ref-type="supplementary-material"}   N/A
  Primers for genotyping                                                                                            See [Table S2](#SD1){ref-type="supplementary-material"}   N/A
  Primers for qPCR                                                                                                  See [Table S2](#SD1){ref-type="supplementary-material"}   N/A
  Software and Algorithms                                                                                                                                                     
  ImageJ                                                                                                            ImageJ ([@R59])                                           RRID:SCR_003070
  MetaXpress Software                                                                                               Molecular Devices                                         RRID:SCR_016654
  CellProfiler Image Analysis Software                                                                              CellProfiler ([@R7])                                      RRID:SCR_007358
  FCS Express Image Cytometry                                                                                       De Novo Software                                          RRID:SCR_016431
  FACSDiva Software                                                                                                 BD Biosciences                                            RRID:SCR_001456
  FlowJo Flow Cytometry Analysis                                                                                    FlowJo                                                    RRID:SCR_008520
  Prism Software                                                                                                    GraphPad                                                  RRID:SCR_002798

###### Highlights

-   Stable molecule levels are more sensitive to cell cycle length than labile ones

-   Stable/labile species can be modeled by the two states of a fluorescent timer (FT)

-   H2B-FT resolves live-cell cycle speed heterogeneity in cultured cells and in mice

-   Fast proliferating cells appear bluer, while slow dividing cells are redder
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